Literature DB >> 17387150

Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.

Joseph Meletiadis1, Theodouli Stergiopoulou, Elizabeth M O'Shaughnessy, Joanne Peter, Thomas J Walsh.   

Abstract

Triple antifungal combinations are used against refractory invasive aspergillosis without an adequate understanding of their pharmacodynamic interactions. We initially studied the in vitro triple combination of voriconazole, amphotericin B, and caspofungin against Aspergillus fumigatus, A. flavus, and A. terreus by a spectrophotometric microdilution broth method after 48 h of incubation. We then analyzed these results with a recently described nonlinear mixture response surface E(max)-based model modified to assess pharmacodynamic interactions at various growth levels. The new model allows flexibility in all four parameters of the E(max) model and is able to describe complex pharmacodynamic interactions. Concentration-dependent pharmacodynamic interactions were found within the triple antifungal combination. At the 50% growth level, synergy (median interaction indices of 0.43 to 0.82) was observed at low concentrations of voriconazole (<0.03 mg/liter) and amphotericin B (</=0.20 mg/liter) and at intermediate concentrations of caspofungin (0.95 to 14.88 mg/liter), whereas antagonism (median interaction indices of 1.17 to 1.80) was found at higher concentrations of voriconazole and amphotericin B. Ternary plot and interaction surface analysis further revealed the complexity of these concentration-dependent interactions. With increasing concentrations of amphotericin B, the synergistic interactions of voriconazole-caspofungin double combination decreased while the antagonistic interactions increased. A similar effect was observed when voriconazole was added to the double combination of amphotericin B and caspofungin. In conclusion, the new nonlinear mixture-amount response surface modeling of the triple antifungal combination demonstrated a net antagonism or synergy against Aspergillus species depending upon drug concentrations and species.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387150      PMCID: PMC1891373          DOI: 10.1128/AAC.00873-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

Review 1.  Aspergillosis. Pathogenesis, clinical manifestations, and therapy.

Authors:  Kieren A Marr; Thomas Patterson; David Denning
Journal:  Infect Dis Clin North Am       Date:  2002-12       Impact factor: 5.982

Review 2.  Antifungal chemotherapy: advances and perspectives.

Authors:  Andreas H Groll; Thomas J Walsh
Journal:  Swiss Med Wkly       Date:  2002-06-15       Impact factor: 2.193

3.  In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

Authors:  Sevtap Arikan; Mario Lozano-Chiu; Victor Paetznick; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Colorimetric assay for antifungal susceptibility testing of Aspergillus species.

Authors:  J Meletiadis; J W Mouton; J F Meis; B A Bouman; J P Donnelly; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

5.  Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Authors:  Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

6.  Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.

Authors:  William R Kirkpatrick; Sofia Perea; Brent J Coco; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.

Authors:  Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

Authors:  Nathan P Wiederhold; Dimitrios P Kontoyiannis; Jingduan Chi; Randall A Prince; Vincent H Tam; Russell E Lewis
Journal:  J Infect Dis       Date:  2004-09-10       Impact factor: 5.226

9.  In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

Authors:  Sofia Perea; Gloria Gonzalez; Annette W Fothergill; William R Kirkpatrick; Michael G Rinaldi; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

Review 10.  Experimental designs for mixtures of chemicals along fixed ratio rays.

Authors:  Stephanie L Meadows; Chris Gennings; W Hans Carter; Dong-Soon Bae
Journal:  Environ Health Perspect       Date:  2002-12       Impact factor: 9.031

View more
  19 in total

Review 1.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

2.  Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Maria Siopi; Nikolaos Siafakas; Sophia Vourli; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

3.  Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii.

Authors:  Julliana Ribeiro Alves Santos; Ludmila Ferreira Gouveia; Erika Linzi Silva Taylor; Maria Aparecida Resende-Stoianoff; Gerson Antônio Pianetti; Isabela Costa César; Daniel Assis Santos
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

4.  Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.

Authors:  Paolo Gaibani; Donatella Lombardo; Michele Bartoletti; Simone Ambretti; Caterina Campoli; Maddalena Giannella; Sara Tedeschi; Matteo Conti; Rita Mancini; Maria Paola Landini; Maria Carla Re; Pierluigi Viale; Russell E Lewis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-06       Impact factor: 3.267

5.  Tobramycin and bicarbonate synergise to kill planktonic Pseudomonas aeruginosa, but antagonise to promote biofilm survival.

Authors:  Karishma S Kaushik; Jake Stolhandske; Orrin Shindell; Hugh D Smyth; Vernita D Gordon
Journal:  NPJ Biofilms Microbiomes       Date:  2016-05-25       Impact factor: 7.290

6.  Optimal drug synergy in antimicrobial treatments.

Authors:  Joseph Peter Torella; Remy Chait; Roy Kishony
Journal:  PLoS Comput Biol       Date:  2010-06-03       Impact factor: 4.475

7.  Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus.

Authors:  Theodouli Stergiopoulou; Joseph Meletiadis; Tin Sein; Paraskevi Papaioannidou; Ioannis Tsiouris; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

8.  Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp.

Authors:  Joanne P Demchok; Joseph Meletiadis; Emmanuel Roilides; Thomas J Walsh
Journal:  Mycoses       Date:  2009-03-07       Impact factor: 4.377

9.  Cell-Cycle-Associated Expression Patterns Predict Gene Function in Mycobacteria.

Authors:  Aditya C Bandekar; Sishir Subedi; Thomas R Ioerger; Christopher M Sassetti
Journal:  Curr Biol       Date:  2020-09-10       Impact factor: 10.834

10.  Fungal biomass is a key factor affecting polymorphonuclear leucocyte-induced hyphal damage of filamentous fungi.

Authors:  Charalampos Antachopoulos; Joanne P Demchok; Emmanuel Roilides; Thomas J Walsh
Journal:  Mycoses       Date:  2009-07-22       Impact factor: 4.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.